Beyond cardiovascular medicine: potential future uses of icosapent ethyl

The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Deepak L, Hull, Mark A, Song, Mingyang, Van Hulle, Carol, Carlsson, Cindy, Chapman, M John, Toth, Peter P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537800/
https://www.ncbi.nlm.nih.gov/pubmed/33061868
http://dx.doi.org/10.1093/eurheartj/suaa119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537800/
https://www.ncbi.nlm.nih.gov/pubmed/33061868
http://dx.doi.org/10.1093/eurheartj/suaa119

Ejemplares similares